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Results: Initially, 65% of subjects received warfadn, but only 49% were on warfarin at 12 
months. Hypertension, CHF, valvular heart disease and a rate control strategy were pre- 
dictors of initial warfarin use; age<55 years, female gender, and history of coronary artery 
or ulcer disease were negative predictors. Predictors of warfarin use at 12 months are 
shown in Table 1. Hypertension, ulcer disease, gender, and physician specialty were not 
predictive. The strongest predictor of warfarin use at 12 months was recurrence of AF. 
Conclusions: Predictors of warfadn use in AF patients include stroke risk factors and 
potential warfarin contraindications. In addition, AF recurrence is a potent predictor for 
warfarin use 12 months after initial diagnosis. 
Table 1. Predictors of warfarin use at 12 months 
Variable Odds ratio (95% CI) P value 
AF recurrence 2.27 (1.51-3.42) 0.0001 
Prior stroke/TIA 2.09 (1.15-3.79) 0.02 
CHF 1.89 (1.25-2.87) 0.003 
Valvular disease 1.78 (1.16-2.66) 0.008 
Age <55 0.49 (0.33-0.74) 0.0008 
1066-106 Compar i son  of  Transesophageal Echocardiography- 
Detected Thromboembolic Risk Markers in Patients 
With Chronic Atrial Fibrillation and Atrial Tachycardia 
According to the SPAF Clinical Risk Stratification: A 
Prospective Study 
Nadia Benyounes, Valdrie Rozenberg, Lydia Djaouti, Charles Smadja, Mohammed 
Khirredine, Ariel Cohen. Saint Antoine University Hospital and Medical School, Paris. 
The thromboembolic (TE) risk of atdal flutter and tachycardias (AFT) has been reported 
as lower than atrial fibrillation (AF). Current guidelines suggest the need for a similar anti- 
coagulant strategy in both groups, This attitude could be balanced by a risk stratification 
using SPAF clinical cdteria and TE echocardiographic markers, 
Objective : We sought to compare the frequency of TE risk markers in patients (Pts) with 
chronic AF and AFT according to the SPAF clinicat criteria for TE dsk stratification. 
Methods : As part of an ongoing prospective study, we evaluated 212 Pts in chronic AF 
and 77 Pts in AFT using transthoracic and transesophagaal echocardiography (TEE). Pts 
were divided into high (n=113 and 43, respectively) and moderate/low (n=99 and 34, 
respectively) SPAF clinical risk groups. The following parameters were evaluated : left 
atdal (LA) and LA appendage (LAA) areas, spontaneous echo contrast (SEC), LAA end 
diastolic emptying velocity (Vel), LA thrombus (Thr) and thoracic aorta atheroma (TAA). 
Results : The main results are summarized in the table 
Chronic AF High Chronic AF Moderate/ AFT High AFT Moderate/ 
risk (n=113) low risk (n=99) risk (n=43) low risk (n=34) 
Mean age 75 ± 11 63.1 _+ 11.5 70.9 + 14.2 63.7 ± 12.9 
(years) 
LA area (cm 2) 24.7 ± 6.3 24.3 ± 6.0 23.7 ± 7.2 22.3 ± 6.9 
LAA area (cm 2) 5.4 + 2.3 5.9 ± 2.6 5.8 ± 2.6 5.4 ± 2.4 
LAA Vel <_25 55 (50.9)* 32 (34.7) 9 (21.9) 8 (25.0) 
cm/s (n,%) 
LA SEC (n,%) 75 (73.5)* 60 (63,8) 18 (45.8) 12 (44.4) 
LAA Thr (n,%) 6 (5.3) 1 (1.0) 2 (4.6) 0 
TAA_> 4 mm 18(17.3) 10(10.4) 10(23.8) 4(13.3) 
(n,%) 
*p< 0.05, high risk AF vs high risk AFT ; ** p< 0.05, moderate/low AF vs moderate/low 
risk AFT. 
Conclusion : LATE risk markers are more frequent in high risk Pts with AE However, 
LA and LAA dilatation and TAA are equally frequent in both high risk Pts. AFT should be 
stratified using the SPAF cdteria, similarly to AF, to help the accurate anticoagulant strat- 
egy. 
1066-119 A Risk Profile for Stroke or Death in Atrial Fibrillation: 
The Framingham Heart Study 
Thomas J. Wane. Joseph M. Massaro, Ralph B. D'Agostino, Daniel Levy, Philip A. Wolf, 
William B. Kannel, Martin G. Larson, Ramachandran S, Vasan, Emelia J, Benjamin, 
Framingham Heart Study, Framingham, Massachusetts. 
BACKGROUND: Individuals with atrial fibrillation (AF) are at increased risk of both 
stroke and death. Risk factors for stroke in AF have been studied, but mainly in subjects 
enrolled in randomized trials. We developed a clinical risk profile, and examined whether 
it could stratify risk among individuals with AF in the community. 
METHODS: We studied 870 subjects (mean age 74, range 55 to 94 years, 46% women) 
from the original and offspring cohorts of the Framingham Heart Study who developed 
AF after 1960, Stepwise Cox proportional hazards models were used to examine clinical 
predictors (obtained from history, physical exam, or ECG) of stroke or death during 5 
years of follow up. Subjects who had a stroke or died within 30 days of AF diagnosis 
were excluded. 
RESULTS: The 5-year event rate was 49%. The following predictors were significant in 
multivariable models: age, systolic blood pressure, smoking, prior myocardial infarction 
or heart failure, and heart murmur. Men in the lowest decile of predicted dsk had a 5-year 
event rate of 9.4%, while those in the highest decile had an event rate of 83.9%. The cor- 
responding values for women were 30.4% and 93.5%. Sex-specific predicted event rates 
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for a representat ive  70 year  old are  shown (Figure). 
CONCLUSION: Using a risk prediction model, it is possible to identify subjects with AF 
who are at particularly high or low risk of stroke or death, 
SSP ~L~O zsl-~ ~zio >ldO >1~0 >~0 
S l~m" N N N Y ,g y 
Nr  CNf /M[  N N N N Y Y 
~m~ N m N N ~ v 
1066-120 Embolic Event Rates After Direct Current Csrdioversion 
in Patients With Atrial Fibrillation and Ineffective 
Anticoagulation: Results of the Ludwlgshsfen 
Observational Atrial Fibrillation Study 
Karlheinz Seidl, Monika Rameken. Margit Vater, Harald Schwacke, Andreas Brandt, 
Caroline Bergmeier, Rail Zahn, Jochen Senges, Heart Center, Ludwigshafen, Germany. 
The Ludwigshafen atrial fibrillation (AF) study is a prospective single center observational 
study on an intention to cardiovert basis, including 1269 consecutive unselected patients 
(pts) with AF. Aim of this substudy was to evaluate the embolic event rate in pts with AF 
and ineffective anticoagulation (IA), in whom electrical cardioversion (CV) was intended. 
IA was defined, if warfarin was given, however INR was < 2, or if no anticoagulation was 
performed. Reasons for performing CV in pts with IA were AF of < 48 h, hemodynamic 
instable AF, or contraindication for anticoagulation. After cardioversion an overlap of war- 
farin therapy and intravenous hepadn was given to maintain adequate anticoagulation 
after CV in pts without contraindications for anticoagulation, 
Results: In 193 pts (15%) anticoagulation therapy was ineffective at the time of the 
intended CV. Transesophageal echocardiography (TEE) was performed in 126 pts, in the 
remaining 67 pts transthoracic echo was performed, A thrombus was found in 10 pts 
(7.9%) of the 126 pts with AF and ineffective anticoagulation. In 53 of the 126 pts (42%) 
TEE revealed spontaneous echo contrast. The grade of spontaneous echo contrast was 
mild in 74%, moderate in 19% and severe in 9%. In 150 of the 196 pts (78%) CV was 
performed, in the remaining 43 pts no CV was performed. In 2 of 150 pts (1.3%) with AF 
and IA a transient ischemic attack occurred in the first 4 weeks after CV. In both pts TEE 
was performed before CV, none of the pts had evidence of left atdal thrombus. In none of 
the 43 pts without CV a thromboembolic omplication occurred. In comparison the rate of 
thromboembolic omplications in the first 4 weeks after CV was 0.8 % (9/1076 pts) in pts 
with AF and effective anticoagulation at least 3 weeks prior to CV. 
Conclusion: 1) In our AF outpatient clinic 15% of the pts with AF had ineffective antico- 
agulation prior to CV. 2) The rate of embolic events in the first 4 weeks after the intended 
CV was 1.3 in pts with ineffective anticoagulation compared to 0.8 in pts with effective 
anticoagulation. 
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1067-107 Changes  in R-R Intervals During Ventricular 
Tachyarrhythmia Storms in Patients With Implantable 
Cardioverter-Defibrillator 
Xiaohong Zhou, Vinod Sharma, Jodi L. KoehIer, Paul J. DeGroot, Walter H. Olson, 
Medtronic, Inc, Minneapolis, Minnesota. 
BACKGROUND: Ventricular tachyarrhythmia (VTNF) storms, defined as greater than or 
equal to 3 episodes within 24 hours, have been reported in patients with implantable car- 
dioverter-defibrillator (ICD). The study objective was to determine whether predisposition 
to VTNF storms could be assessed from changes in episode related cardiac cycle 
lengths. METHODS: ICD patients (n=220) with coronary artery disease were followed for 
6.9±3.6 months post-implant. Stored electrograms were retrospectively reviewed and all 
true VTNF episodes, each of which was successfully terminated, were identified. Two 
types of changes in mean R-R interval (R-R) were calculated: (1) Delta-RR1, {[(mean R- 
R immediately prior to an episode)-(baseline mean R-R)]/(baseline mean R-R)}*100%, 
and (2) Delta-RR2, ([(mean R-R immediately after an episode)-(mean R-R immediately 
prior to an episode)]/(mean R-R immediately prior to an episode)}*100%. Baseline mean 
R-R was obtained at office visit and the mean R-Rs immediately prior to and immediately 
after an episode were obtained from ICD electrograms (excluding premature contrac- 
tion). RESULTS: There were a total of 629 episodes in 72 patients. Forty-one patients 
had all discrete episodes (total 91 episodes, group 1) without storms. Thirty-one patients 
experienced at least one storm and had a total of 538 episodes (group 2). Of 538 epi- 
sodes in group 2, 405 episodes (75%, group 2a) occurred in 57 storms and the remaining 
133 episodes were discrete (25%, group 2b). Each VTNF storm consisted of 7.1±5.7 
episodes (median = 5). The Delta-RR1 was -10.7±23.6% for group 1 and -27.3±15.4% 
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for group 2 (p<O.0001), and was -30.1±14.6% for group 2a and -21.3±10.9% for group 
2b (p<O.O001). The Delta-RR2 was +3.6±12.6% for group I and -4.0±14.6% for group 2 
(p<O.O01), and was -5.8±12.3% for group 2a and +0.3±17.6% for group 2b (p=0.O01). 
CONCLUSION: Majority of VTNF episodes occurred in forms of storms. Episodes during 
storms were associated with greater changes in R-R intervals compared to discrete epi- 
sodes. This raises the possibility of using changes in R-R intervals as an indicator to 
determine patients' propensity to experience VT/VF storms. 
1067-108 Is One Successful VF Conversion Adequate for Sate ICD 
Implantation? 
Michael R. Gold. Stephen R. Shorofsky, Eric J. Rashba, University of Maryiand, 
Baltimore, Maryland. 
Background: Multiple successful conversions of ventricular fibrillation (VF) have been 
recommended as the minimum criteria for safe defibrillator (ICD) implantation, because 
of the statistical probability of success curve for defibrillation, We postulated that a single 
success at a low energy (14 J) would provide an adequate safety margin for devices pro- 
grammed to maximum energy (31 J). 
Methods: The Low Energy Safety Study (LESS) enrolled 720 patients at 32 centers 
undergoing initial ICD implantation with a dual coil transvenous lead and active pulse 
generator (triad configuration). At implant the defibrillation threshold (DFT) was deter- 
mined using a rigorous protocol beginning at 14 J that required at least 4 shocks to deter- 
mine the DFT++. Half of all patients were then randomized to chronic programming with 
all shocks at maximum energy and the conversion rates for spontaneous VF (ventricular 
arrhythmias with rates > 200 bpm) were evaluated, 
Results: In LESS, 318 patients were randomized to all shocks at 31 J, including 254 with 
success on their initial attempt at 14 J. During a mean follow-up duration of 24+12 
months, the full cohort experienced 112 spontaneous episodes of VF, of which 103 (92%) 
were successfully converted with the first shock and 109 (97.3%) were successfully con- 
varied with the first 2 shocks. In the subset with the 14 J initial attempt success, 66 spon- 
taneous VF episodes Occurred, of which 59 (89,4%) were successfully converted with 
the first shock and 64 (97%) were successfully converted with the first 2 shocks. The 
device eventually converted all episodes in both groups. 
Conclusions: An implant criterion of one success at 14J appears adequate and 
deserves further study. 
1067-109 Cl inical  Features and Causes of Coaxial Polyurethane 
ICD Lead Failure 
Norman Ratliff, Robed G. Hauser, G. Frank O. Tyers, David L. Hayes, Andrew E. 
Epstein, Stephen C. Vlay, John Hayes, Seymour Furman, Jay Gross, Victor Parsonnet, 
David Cannom, Muiticenter Regist~ Minneapolis, Minnesota, Minneapolis Heart 
institute Foundation, Minneapolis, Minnesota. 
Background: The failure of an ICD lead may prevent the detection or termination of VT/ 
VF, or the treatment of a bradyarrhythmia. Coaxial polyurethane ICD leads (ICD-L), 
Transvene RV models 6936/6966 (Medtronic, Inc.) were introduced in 1991. According to 
the manufacturer, 24, 625 U.S. implants have been registered, and an estimated 14,400 
remain active. Recent reports suggest that these ICD-L may be prone to failure. Meth- 
ods: We searched the Multicenter Registry and FDA's MAUDE (Manufacturer and User 
Facility Device Experience) databases for ICD-L device failures. Lead complications due 
to infection, displacement, and iatregenic causes were excluded. As of September 2001, 
the Registry had received 22 reports from 8 NoAh American centers, and MAUDE con- 
tained 438 reports, including 79% from the manufacturer and 21% from user facilities. 
Results: The mean time to failure for these 460 leads was 3.3+/-2.0 years (range:<1 
month-8 years). The primary signs of failure were available for 299 events: inappropriate 
shocks or antitachycardia therapy-39% (118/299), oversensing-15% (46/299), under- 
sensing-7% (20/299), failure to defibrillate-3% (8/299), non-capture or high threshold- 
15% (45/299), impedance change-15% (46/299), and other-5% (16/299). Major clinical 
events included 10 deaths and 17 life-threatening emergencies. Specific causes of fail- 
ure were reported for 267 ICD-L: conductor fracture-68% (181/267), disrupted insulation- 
31% (84/267), and fixation mechanism-1% (2/267); clavicular crush was noted in 6% (16/ 
267). Analyses of 110 ICD-L that were removed and returned to the manufacturer 
revealed that fracture often involved the high voltage coil (37/72) or multiple conductors 
(17/72) and the 80A polyurethane middle (18/38) or outer (17/38) insulation. Conclu- 
sion: ICD-L appear to fail for reasons related to the coaxial design, 80A polyurethane 
insulation, and implant technique. Because of the potentially serious clinical conse- 
quences of ICD-L failure, studies are needed to determine the likelihood of failure, and to 
guide the safe management of patients who have these models. 
1067-110 Ventricular Arrhythmia Recurrence After Quiescent 
Periods in Patients With Impiantable Cardioverter- 
Defibrillators 
Alan X. Zhu, Cengiz Ermis, David G. Benditt, Scott Sakaguchi, Cardiac Arrhythmia 
Center University of Minnesota Cardiovascular Division, Minneapolis. 
Background: Current AHNNASPE recommendations suggest a 6-month symptomatic 
arrhythmia event free interval following placement of an implantable cardioverter defibril- 
lator (ICD) before resumption of driving. An additional 6-month observation period is 
advised if arrhythmia recurs, tn this study, we postulated that the quiescent time to recur- 
rence of arrhythmia may be useful to predict risk of future arhythmia recurrences in ICD 
patients (pts). 
Methods: Data from 254 consecutive ICD pts was reviewed. The interval after ICD 
implant to each ventricular tachycardia(VT)/venthcular fib illation(VF) episode treated by 
ICD pacing or shock was identified. Pts (mean age 64+14.1 years) were followed at 3 to 
6 month intervals for an average of 24_+14.6 months. Mean left ventricle ejection fraction 
(LVEF) was 35_+14.5%. 
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Results: Indication for ICD implant was spontaneous ustained VT (52%) or VF (35%), or 
inducible sustained V'I" (13%). One hundred forty (55%) pts experienced at least one ICD 
treated ventricular arrhythmia. A total of 1920 episodes were treated, VF accounting for 
285 (15%). Amiodarone and ~ blockers, including sotalol were used in 30% and 58% o1 
pts at discharge, and 32% and 58% at the end of follow up penod, respectively. The 
recurrence rates for tCD treated VT/VF during a 6 month period following quiescence 
periods of 3, 6, 9 and 12 months immediately post implant were 24%, 21%, 19% and 
17%, respectively. Conversely, a 6-month quiescent period starting after a treated 
arrhythmia was associated with 45% recurrence risk (p=0.001 vs risk with a 'no arrhyth- 
mia' 6 month period). Logistic regression identified that a low LVEF (<30%) was the only 
significant predictor of arrhythmia recurrence (p=0.02). 
Conclusion: Subsequent VT/VF recurrence risk in ICD pts decreases inversely with the 
length of arrhythmia free period. Fudher, for comparable followup periods, a quiescent 
period immediateJy after implant is associated with a lower recurrence risk than is a simi- 
lar length quiescent period after a treated arrhythmia. However, even long quiescent peri- 
ods are ultimately associated with worrisome VT/VF recurrence. This finding requires 
consideration when providing driving advice for ICD pts. 
1067-111 The Relation of Capacitor Charge Time and Output 
Energy to Battery Voltage Compared in Multiple 
Implantable Cardioverter Defibrillator Pulse Generators 
Claudia Williams, Thomas A. Maffioni, Lee Strickland, Marwan Bahu, Arizona Heart 
Institute, Phoenix, Arizona. 
Background: Comparative data is lacking on implantable cardioveder-defibrillator (ICD) 
systems on the effect of battery voltage on capacitor charge time and output energy. 
Methods: ICD pulse generators were attached to a rhythm simulator and allowed to pace 
and shock into fixed loads. Each ICD was programmed to deliver shocks at 4 energy lev- 
els with 5 episodes for each level (20 episodes/day). Battery voltage was measured at 
the beginning of every sequence and charge time was recorded immediately after each 
shock. The shock output was measured at each energy level by oscilloscope and deliv- 
ered energies calculated. Delivered energy was then compared to programmed outputs 
as well as battery voltage. This was continued until battery depletion. The ICDs tested 
were: Gem DR , Gem III DR (Medtronic), Photon (St. Jude) and Prizm DR, Prizm II DR 
(Guidant). 
Results: A family of graphs was generated showing the relationship of battery voltage to 
charge time at various energy levels (example). ICDs which program delivered energy 
had an error in measured energy as high as 10%, independent of battery voltage. 
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Conclusions: An inverse relationship of battery voltage to capacitor charge time was 
found with differences in charge time between devices remaining constant. Discrepancy 
between programmed delivered energy and measured energy was highest in devices 
with shorter charge times and programmable delivered energy. Measured shock output 
energies were stable throughout the life of all devices. 
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1068-112 Postural Response of Low Frequency Component of 
Heart Rate Variability Is an Increased Risk for Mortality 
in Patients With Coronary Artery Disease 
Jun-ichiro Hayano, Seiji Mukai, Seiichiro Sakata, Hidekatsu Fukuta, ShinU Ishihara, 
Genjiro Kimura, Third Department of Internal Medicine, Nagoya City University Medical 
School, Nagoya, Japan. 
Background: Analysis of heart rate variability (HRV) during head-up tilt testing (HUT) is 
widely used as a cardiac autonomic function test, but its prognostic value in coronary 
artery disease (CAD) is unknown. We examined if autonomic functions assessed by HRV 
during a standardized HUT predicts nsk for death in patients with stable CAD. 
Methods: In a cohort of 250 patients with CAD undergoing elective coronary angiogra- 
phy, we analyzed HRV during standardized HUT under paced breathing with discontinu- 
ing all medications. The patients were subsequently followed up for 99 months and the 
prognostic value of HRV were examined. 
Results: During the followed-up, there were 25 deaths (10%);13 from cardiac causes 
and 12 from non-cardiac causes. Cox regression analysis adjusted for cardiovascular 
risks revealed that increased postural change (upright minus supine) in low-frequency 
power (LF) predicted an increased risk for cardiac death (RR [95% CI] per l-In[ms 2] 
increment, 4.36 [1.64-11.6]), while neither high-frequency component nor its response to 
HUT predicted any form of death. When the patients were tdchotomized by the level of 
postural LF change (large drop< 0.6 In[ms2], small drop and rise>0 In[ms2]), the 3 groups 
did not differ in clinical features or CAD severity at baseline or coronary interventions dur- 
